X
|
QUARTERLY
REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
|
_____
|
TRANSITION
REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
Commission
File Number
|
|
0-50481
|
|
AEOLUS
PHARMACEUTICALS, INC.
|
|
(Exact
Name of Registrant as Specified in Its
Charter)
|
|
|
Delaware
|
|
56-1953785
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
23811 Inverness Place
Laguna Niguel, California
|
|
92677
|
(Address
of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(Registrant’s
Telephone Number, Including Area Code)
949-481-9825
|
|
|
Class
|
Outstanding
as of
July
27, 2007
|
Common
Stock, par value $.01 per share
|
31,952,749
shares
|
|
|
|
Page
|
PART
I. FINANCIAL
INFORMATION
|
|||
|
Item
1.
|
Financial
Statements
|
|
|
|
|
|
|
|
Statement
Regarding Financial
Information
|
3
|
|
|
|
|
|
|
Condensed
Consolidated Balance
Sheets as of June
30, 2007 (unaudited)
and September 30, 2006
|
4
|
|
|
|
|
|
|
Condensed
Consolidated Statements
of Operations for the Three Months and
Nine Months ended
June
30, 2007
and 2006
(unaudited)
|
5
|
|
|
|
|
|
|
Condensed
Consolidated Statements
of Cash Flows for the Nine Months
ended June 30,
2007
and 2006
(unaudited)
|
6
|
|
|
|
|
|
|
Notes
to Condensed Consolidated
Financial Statements
|
7
|
|
|
|
|
|
Item
2.
|
Management’s
Discussion and
Analysis of Financial Condition and Results of
Operations
|
11
|
|
|
|
|
|
Item
3.
|
Quantitative
and Qualitative
Disclosures About Market Risk
|
14
|
|
|
|
|
|
Item
4.
|
Controls
and
Procedures
|
14
|
|
|
|
|
PART
II. OTHER
INFORMATION
|
|||
|
Item
1.
|
Legal
Proceedings
|
14
|
|
|
|
|
|
Item
1A.
|
Risk
Factors
|
14
|
|
|
|
|
|
Item
2.
|
Unregistered
Sales of Equity
Securities and Use of Proceeds
|
14
|
|
|
|
|
|
Item
3.
|
Defaults
Upon Senior Securities
|
14
|
|
|
|
|
|
Item
4.
|
Submission
of Matters to a Vote
of Security Holders
|
14
|
|
|
|
|
|
Item
5.
|
Other
Information
|
14
|
|
|
|
|
|
Item
6.
|
Exhibits
|
15
|
|
|
|
|
|
SIGNATURES
|
15
|
AEOLUS
PHARMACEUTICALS, INC.
|
||||||||
|
|
|
||||||
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
||||||||
(In
thousands, except shares and per share data)
|
||||||||
|
|
|
||||||
|
June
30,
|
September
30,
|
||||||
|
2007
|
2006
|
||||||
|
(Unaudited)
|
|
||||||
ASSETS
|
||||||||
Current
assets:
|
|
|
||||||
Cash
and cash equivalents
|
$ |
2,173
|
$ |
3,324
|
||||
Prepaids
and other current assets
|
298
|
104
|
||||||
Total
current assets
|
2,471
|
3,428
|
||||||
|
||||||||
Investment
in CPEC LLC
|
126
|
126
|
||||||
Total
assets
|
$ |
2,597
|
$ |
3,554
|
||||
|
||||||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable
|
$ |
163
|
$ |
868
|
||||
Accrued
expenses
|
5
|
23
|
||||||
Current
maturity of long-term note payable
|
-
|
956
|
||||||
Total
current liabilities
|
168
|
1,847
|
||||||
|
||||||||
Long-term
note payable
|
471
|
-
|
||||||
Total
liabilities
|
639
|
1,847
|
||||||
Commitments
and contingences
|
||||||||
|
||||||||
Stockholders'
equity:
|
||||||||
Preferred
stock, $.01 par value per share, 10,000,000 shares
authorized:
|
||||||||
Series
B nonredeemable convertible preferred stock, 600,000
shares
|
||||||||
authorized;
475,087 shares issued and outstanding at June 30,
|
||||||||
2007
and September 30, 2006
|
5
|
5
|
||||||
Common
stock, $.01 par value per share, 150,000,000 shares
authorized;
|
||||||||
31,952,749 and 29,265,249 shares issued and outstanding
at
|
||||||||
June
30, 2007 and September 30, 2006, respectively
|
320
|
293
|
||||||
Additional
paid-in capital
|
156,537
|
154,311
|
||||||
Accumulated
deficit
|
(154,904 | ) | (152,902 | ) | ||||
Total
stockholders' equity
|
1,958
|
1,707
|
||||||
Total
liabilities and stockholders' equity
|
$ |
2,597
|
$ |
3,554
|
||||
|
||||||||
The
accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
|
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
||||||||||||||||
(Unaudited)
|
||||||||||||||||
(In
thousands, except per share data)
|
||||||||||||||||
Three
Months Ended
|
Nine
Months Ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Revenue
|
||||||||||||||||
Grant
income
|
$ |
-
|
$ |
-
|
$ |
-
|
$ |
92
|
||||||||
Costs
and expenses:
|
||||||||||||||||
Research
and development
|
192
|
419
|
869
|
2,677
|
||||||||||||
General
and administrative
|
320
|
524
|
1,396
|
1,571
|
||||||||||||
Total
costs and expenses
|
512
|
943
|
2,265
|
4,248
|
||||||||||||
Loss
from operations
|
(512 | ) | (943 | ) | (2,265 | ) | (4,156 | ) | ||||||||
Interest
income (expense), net
|
3
|
(10 | ) |
38
|
(29 | ) | ||||||||||
Equity
in income of CPEC LLC
|
-
|
-
|
-
|
433
|
||||||||||||
Other
income
|
-
|
17
|
225
|
53
|
||||||||||||
Increase
in fair value of common stock warrants
|
-
|
(2,216 | ) |
-
|
(1,815 | ) | ||||||||||
Net
loss
|
(509 | ) | (3,152 | ) | (2,002 | ) | (5,514 | ) | ||||||||
Preferred
stock dividend accreted
|
-
|
(26 | ) |
-
|
(81 | ) | ||||||||||
Net
loss attributable to common stockholders
|
$ | (509 | ) | $ | (3,178 | ) | $ | (2,002 | ) | $ | (5,595 | ) | ||||
Net
loss per weighted share attributable to common
stockholders:
|
||||||||||||||||
(basic
and diluted)
|
$ | (0.02 | ) | $ | (0.17 | ) | $ | (0.07 | ) | $ | (0.36 | ) | ||||
Weighted
average common shares outstanding:
|
||||||||||||||||
Basic
and diluted
|
30,429
|
18,234
|
29,661
|
15,450
|
||||||||||||
The
accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
|
AEOLUS
PHARMACEUTICALS, INC.
|
||||||||
|
|
|
||||||
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
||||||||
(Unaudited)
|
||||||||
(In
thousands)
|
||||||||
|
|
|
||||||
|
Nine
Months Ended
|
|||||||
|
June
30,
|
|||||||
|
2007
|
2006
|
||||||
Cash
flows from operating activities:
|
|
|
||||||
Net
loss
|
$ | (2,002 | ) | $ | (5,514 | ) | ||
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
||||||||
Noncash
compensation
|
471
|
264
|
||||||
Noncash
interest and financing costs
|
40
|
66
|
||||||
Noncash
licensing fee
|
-
|
12
|
||||||
Forgiveness
of note payable
|
(225 | ) |
-
|
|||||
Equity
income of CPEC LLC
|
-
|
(433 | ) | |||||
Decrease
in fair value of common stock warrants
|
-
|
1,815
|
||||||
Change
in assets and liabilities:
|
||||||||
Accounts
receivable, prepaids and other assets
|
(194 | ) | (20 | ) | ||||
Accounts
payable and accrued expenses
|
(723 | ) | (337 | ) | ||||
Net
cash used in operating activities
|
(2,633 | ) | (4,147 | ) | ||||
|
||||||||
Cash
flows from financing activities:
|
||||||||
Payment
of note payable
|
(300 | ) |
-
|
|||||
Proceeds
from dividend from CPEC LLC
|
-
|
315
|
||||||
Net
proceeds from issuance of Series A Preferred Stock
|
-
|
2,413
|
||||||
Net
proceeds from issuance of common stock
|
1,761
|
4,754
|
||||||
Proceeds
from exercise of stock options
|
21
|
42
|
||||||
Net
cash provided by financing activities
|
1,482
|
7,524
|
||||||
|
||||||||
Net
decrease in cash and cash equivalents
|
(1,151 | ) |
3,377
|
|||||
Cash
and cash equivalents at beginning of period
|
3,324
|
626
|
||||||
Cash
and cash equivalents at end of period
|
$ |
2,173
|
$ |
4,003
|
||||
|
||||||||
|
||||||||
The
accompanying notes are integral part of these unaudited condensed
consolidated financial statements.
|
Number
of Shares
|
Exercise
Price
|
Expiration
Date
|
||
50,000
|
$ 0.50
|
May
2011
|
||
2,500,000
|
$ 0.50
|
November
2010
|
||
2,186,668
|
$ 0.75
|
May
2012
|
||
7,000,000
|
$ 0.75
|
June
2011
|
||
50,000
|
$ 1.00
|
May
2011
|
||
35,000
|
$ 1.00
|
July
2008
|
||
50,000
|
$ 1.50
|
May
2011
|
||
50,000
|
$ 2.00
|
May
2011
|
||
50,000
|
$ 2.50
|
May
2011
|
||
410,400
|
$ 2.50
|
April
2009
|
||
1,641,600
|
$ 4.00
|
April
2009
|
||
1,759
|
$ 19.90
|
October
2008
|
||
14,025,427
|
$ 1.15
|
|
Shares
|
Weighted
Average Exercise Price
|
Weighted
Average Remaining Contractual Term
|
Aggregate
Intrinsic Value
|
|||||||||
Outstanding
at September 30, 2006
|
3,071,806
|
$ |
3.25
|
7.7
years
|
$ |
22,000
|
|||||||
Granted
|
748,000
|
$ |
0.61
|
||||||||||
Exercised
|
(20,833 | ) | $ |
1.00
|
|||||||||
Forfeited
|
(477,356 | ) | $ |
0.64
|
|||||||||
Outstanding
at June 30, 2007 (unaudited)
|
3,321,617
|
$ |
3.04
|
7.0
years
|
$ |
119,000
|
|||||||
Exercisable
at June 30, 2007 (unaudited)
|
3,119,117
|
$ |
3.19
|
6.9
years
|
$ |
87,000
|
|
|
Options
Outstanding
|
|
Options
Exercisable
|
||||||||
Range
of Exercise Prices
|
|
Number
Outstanding at June 30, 2007
|
|
Weighted
Average Exercise Price
|
|
Weighted
Average Remaining Contractual Life
|
|
Number
Exercisable at
June
30, 2007
|
|
Weighted
Average Exercise Price
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.38
- 0.75
|
592,461
|
|
$
|
0.68
|
|
8.5
years
|
|
454,961
|
|
$
|
0.69
|
|
$0.78
- $0.83
|
133,000
|
|
$
|
0.80
|
|
9.0
years
|
|
125,500
|
|
$
|
0.80
|
|
$0.85
|
|
335,744
|
|
$
|
0.85
|
|
8.3
years
|
|
278,244
|
|
$
|
0.85
|
$0.86
- $1.12
|
|
342,477
|
|
$
|
0.95
|
|
8.2
years
|
|
342,477
|
|
$
|
0.95
|
$1.13
- $1.45
|
|
52,450
|
|
$
|
1.16
|
|
7.6
years
|
|
52,450
|
|
$
|
1.16
|
$1.50
|
|
1,256,015
|
|
$
|
1.50
|
|
6.1
years
|
|
1,256,015
|
|
$
|
1.50
|
$1.52
- $5.00
|
|
374,556
|
|
$
|
2.74
|
|
7.0
years
|
|
374,556
|
|
$
|
2.74
|
$5.10
- $31.88
|
|
186,115
|
|
$
|
18.84
|
|
4.0
years
|
|
186,115
|
|
$
|
18.84
|
$50.9375
|
|
2,999
|
|
$
|
50.94
|
|
2.8
years
|
|
2,999
|
|
$
|
50.94
|
$51.25
|
45,800
|
|
$
|
51.25
|
|
2.8
years
|
|
45,800
|
|
$
|
51.25
|
|
$0.38
- $51.25
|
3,321,617
|
|
$
|
3.04
|
|
7.0
years
|
|
3,119,117
|
|
$
|
3.19
|
For
the nine months
June
30,
|
||||||||
2007
|
2006
|
|||||||
Research
and development expenses
|
$ |
161
|
$ |
31
|
||||
General
and administrative expenses
|
283
|
191
|
||||||
Total
stock-based compensation expense
|
$ |
444
|
$ |
222
|
For
the nine months June 30,
|
||||
2007
|
2006
|
|||
Dividend
yield
|
0%
|
0%
|
||
Expected
volatility
|
191
- 195%
|
187
– 190%
|
||
Risk-free
interest rate
|
4.5%
- 5.1%
|
4.4%
- 5.2%
|
||
Expected
option life after shares are vested
|
10
years
|
10
years
|
Exhibit
#
|
|
Description
|
4.1
|
Registration
Rights Agreement dated May 22, 2007 by and among the Company and
each of
the Purchasers whose names appear on the Schedule attached
thereto (incorporated by reference to Exhibit 4.1 to the Company's
Form 8-K dated May 22, 2007).
|
|
10.1
|
Securities
Purchase Agreement dated May 22, 2007 by and among the Company
and the
investors whose names appear on the signature pages
thereof (incorporated by reference to Exhibit 10.1 to the Company's
Form 8-K dated May 22, 2007).
|
|
10.2
|
Form
of Warrant to Purchase Common Stock dated May 22, 2007 (incorporated
by
reference to Exhibit 10.2 to the Company's Form 8-K dated May 22,
2007).
|
|
10.3
|
Letter
Agreement dated April 30, 2007 by and between the Company and Rodman
and
Renshaw, LLC (incorporated by reference to Exhibit 10.3 to the
Company's Form 8-K dated May 22, 2007).
|
|
10.4
|
Convertible
Promissory Note dated February 7, 2007 issued by Aeolus Pharmaceuticals,
Inc. to Elan Pharma International Ltd. (incorporated by reference to
Exhibit 10.43 to the Company's Form S-1 dated June 4,
2007).
|
|
31.1
|
Certification
of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a)
and 15d-14(a).
|
|
31.2
|
Certification
of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a)
and 15d-14(a).
|
|
32.1
|
Certification
by the Chief Executive Officer and Chief Financial Officer pursuant
to 18
U.S.C. §1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.
|
Date: July
30,
2007
|
By:
|
/s/
John L. McManus
|
|
|
John
L. McManus
President
and Chief Executive Officer
(Principal
Executive Officer)
|
|
|
|
Date: July
30,
2007
|
By:
|
/s/
Michael P. McManus
|
|
|
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary
(Principal
Financial and Accounting
Officer)
|